Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On November 7, 2024, NeuroBo Pharmaceuticals, Inc. (NRBO) announced financial results for the third quarter of 2024 and provided a business update.</li><li>The next clinical milestone will be the release of topline data from the Phase 2a trial of DA-1241 in MASH.</li><li>The trial is exploring the efficacy of DA-1241 both as a monotherapy and in combination with sitagliptin.</li></ul>

On November 7, 2024, NeuroBo Pharmaceuticals, Inc. (NRBO) announced financial results for the third quarter of 2024 and provided a business update.The next clinical milestone will be the release of topline data from the Phase 2a trial of DA-1241 in MASH.The trial is exploring the efficacy of DA-1241 both as a monotherapy and in combination with sitagliptin.

NRBO:  Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024 

MetaVia

NRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024